Rituximab: mechanism of action
- PMID: 20350658
- PMCID: PMC2848172
- DOI: 10.1053/j.seminhematol.2010.01.011
Rituximab: mechanism of action
Abstract
Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies. Despite its undeniable therapeutic value, we still do not fully understand the mechanisms of action responsible for rituximab's anti-tumor effects. Direct signaling, complement-mediated cytotoxicity (CMC), and antibody-dependent cellular cytotoxicity (ADCC) all appear to play a role in rituximab efficacy. In vitro, animal model and clinical data addressing each of these mechanisms of action are reviewed, as are data speaking to the complexity of interactions between these mechanisms. Taken together, these data suggest different mechanisms are likely important in different scenarios. Study of the complex mechanisms of action that contribute to the clinical efficacy of rituximab have led to novel clinical trials including novel combinations, schedules, and generation of additional antibodies designed to have even greater effect. Such studies need to be accompanied by rigorous correlative analysis if we are to understand the importance of various mechanisms of action of rituximab and use that information to improve on what is already an indispensable component of therapy.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2848172/bin/nihms-171257-f0001.gif)
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2848172/bin/nihms-171257-f0001.gif)
Similar articles
-
[Rituximab: mechanism of action and resistance].Bull Cancer. 2007 Feb;94(2):198-202. Bull Cancer. 2007. PMID: 17337389 French.
-
Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.Cancer Sci. 2009 Dec;100(12):2411-8. doi: 10.1111/j.1349-7006.2009.01327.x. Epub 2009 Aug 25. Cancer Sci. 2009. PMID: 19758394 Free PMC article.
-
Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.J Immunother. 2009 Jul-Aug;32(6):622-31. doi: 10.1097/CJI.0b013e3181ab23f1. J Immunother. 2009. PMID: 19483647
-
The mechanisms of action of rituximab in the elimination of tumor cells.Semin Oncol. 2003 Feb;30(1 Suppl 2):3-8. doi: 10.1053/sonc.2003.50025. Semin Oncol. 2003. PMID: 12652458 Review.
-
Antigenic modulation and rituximab resistance.Semin Hematol. 2010 Apr;47(2):124-32. doi: 10.1053/j.seminhematol.2010.01.006. Semin Hematol. 2010. PMID: 20350659 Free PMC article. Review.
Cited by
-
Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity.NPJ Precis Oncol. 2024 May 20;8(1):108. doi: 10.1038/s41698-024-00595-w. NPJ Precis Oncol. 2024. PMID: 38769377 Free PMC article.
-
Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion.Cell Oncol (Dordr). 2024 Apr 25. doi: 10.1007/s13402-024-00945-7. Online ahead of print. Cell Oncol (Dordr). 2024. PMID: 38662336
-
Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.Front Immunol. 2024 Apr 4;15:1363102. doi: 10.3389/fimmu.2024.1363102. eCollection 2024. Front Immunol. 2024. PMID: 38638442 Free PMC article. Review.
-
Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.Blood Cancer J. 2024 Apr 18;14(1):67. doi: 10.1038/s41408-024-01050-6. Blood Cancer J. 2024. PMID: 38637557 Free PMC article.
-
Is There a Place for Apheresis in the Management of Idiopathic Membranous Nephropathy? A Report of Three Cases and Literature Review.J Pers Med. 2024 Feb 26;14(3):249. doi: 10.3390/jpm14030249. J Pers Med. 2024. PMID: 38540991 Free PMC article.
References
-
- Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma [see comments] J Clin Oncol. 1997;15(10):3266–74. - PubMed
-
- McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825–33. - PubMed
-
- Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–7. - PubMed
-
- Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42. - PubMed
-
- Maloney DG, Grillolopez AJ, White CA, et al. Idec-C2b8 (Rituximab) Anti-Cd20 Monoclonal Antibody Therapy Patients With Relapsed Low-Grade Non-Hodgkins Lymphoma. Blood. 1997;90(6):2188–2195. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources